



HAL
open science

Intestinal toxicity of deoxynivalenol is limited by *Lactobacillus rhamnosus* RC007 in pig jejunum explants

Gisela Romina García, Delphine Payros, Philippe Pinton, Cecilia Ana Dogi,
Joëlle Laffitte, Manon Neves, María Laura González Pereyra, Lilia Renée
Cavaglieri, Isabelle P. Oswald

► To cite this version:

Gisela Romina García, Delphine Payros, Philippe Pinton, Cecilia Ana Dogi, Joëlle Laffitte, et al.. Intestinal toxicity of deoxynivalenol is limited by *Lactobacillus rhamnosus* RC007 in pig jejunum explants. *Archives of Toxicology*, 2018, 92 (2), pp.983-993. 10.1007/s00204-017-2083-x . hal-03331263

HAL Id: hal-03331263

<https://ut3-toulouseinp.hal.science/hal-03331263>

Submitted on 1 Sep 2021

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial - NoDerivatives 4.0
International License

INTESTINAL TOXICITY OF DEOXYNIVALENOL IS LIMITED BY *Lactobacillus rhamnosus* RC007 IN PIG JEJUNUM EXPLANTS

G.R. GARCÍA^{1,2,+}, D. PAYROS^{3,+}, P. PINTON³, C.A. DOGI^{1,2}, J. LAFFITTE³, M. NEVES³, M.L. GONZÁLEZ PEREYRA^{1,2}, L.R. CAVAGLIERI^{1,2}, I.P. OSWALD^{3*}

¹Departamento de Microbiología e Inmunología. Universidad Nacional de Río Cuarto. Ruta 36 km.601. (5800) Río Cuarto. Córdoba. Argentina. ²Consejo Nacional de Investigaciones Científicas y Tecnológicas (CONICET), Argentina. ³Toxalim (Research Center in Food Toxicology) Université de Toulouse, INRA, ENVT, INP-Purpan, UPS Toulouse, France.

+ equally contributed

* corresponding author: Isabelle P. OSWALD, ToxAlim, Research Center in Food Toxicology, UMR INRA 1331, 180 chemin de Tournefeuille, BP93173, 31027 Toulouse cedex 03 France. Tel. 33 (0)5 82 06 63 66. e-mail: isabelle.oswald@inra.fr

Funding. This work was supported in part by the french ANR (Agence Nationale de la Recherche) projects ImBio (ANR-13-CESA-0003-03), CaDON (ANR-15-CE21-0001-02) and ANPCYT-PICT1606/12.

Abstract

Probiotics have been explored to stimulate gut health in weaned pigs, when they started to consume solid diet where mycotoxins could be present. The aim of this study was to evaluate the effect of *Lactobacillus rhamnosus* RC007 on the intestinal toxicity of deoxynivalenol (DON) in an *ex vivo* model. Jejunal explants, obtained from 5 weeks old crossbred castrated male piglets, were kept as control, exposed for 3 hours to 10 μ M DON, incubated for 4 hours with 10⁹ CFU/mL *L. rhamnosus*, or pre-incubated 1 hour with 10⁹ *L. rhamnosus* and exposed to DON. Histological lesions were observed, para- and trans-cellular intestinal permeability was measured in Ussing chambers. The expression levels of mRNA encoding 6 inflammatory cytokines (CCL20, IL-10, IL-1 β , TNF α , IL-8 and IL-22) were determined by RT-PCR. The expressions of the phosphorylated MAP Kinases p42/p44 and p38 were assessed by immunoblotting. Exposure to DON induced histological changes, significantly increased the expression of CCL20, IL-1 β , TNF α , IL-8, IL-22 and IL-10, increased the intestinal paracellular permeability and activated MAP Kinases. Incubation with *L. rhamnosus* alone did not have any significant effect. By contrast, the pre-incubation with *L. rhamnosus* reduced all the effects of DON: the histological alterations, the pro-inflammatory response, the paracellular permeability and the phosphorylation of MAP Kinases. Of note, *L. rhamnosus* did not adsorb DON and only slightly degrade the toxin. In conclusion, *L. rhamnosus* RC007 is a promising probiotic which, included as feed additive, can decrease the intestinal toxicity of DON.

Introduction

The Food and Agricultural Organization estimates that mycotoxins contaminate 25% of the world's agricultural commodities. Mycotoxins have been found in a wide range of food commodities, such as cereals, root crops, nuts and seeds, dairy products and meat products, as well as in animal feeds and ingredients used to produce them. The most significant mycotoxins in naturally contaminated foods and feeds are aflatoxins, ochratoxins, trichothecenes, zearalenone and fumonisins (Dänicke 2002). Among the trichothecenes, deoxynivalenol (DON) is the major mycotoxin produced by *Fusarium* fungi, and is commonly found in cereals and grains (Sobrova et al. 2010). Exposure to DON can induce gastrointestinal inflammation and necrosis within the intestinal tract and disturbs the gut barrier function (Cano et al. 2013; Pinton and Oswald 2014). At the molecular level, DON disrupts normal cell function by inhibiting protein synthesis and by activating critical cellular kinases involved in signal transduction related to proliferation, differentiation, and apoptosis (Payros et al. 2016). Animal studies showed that acute exposure to high doses of DON results in diarrhea, vomiting, leukocytosis, gastrointestinal hemorrhage and ultimately death whereas short-term and sub-chronic exposure to DON decreased body weight, weight gain, and feed consumption. Pigs are readily exposed to this toxin through their cereal-rich diet and they are the most sensitive species to this toxin.

Weaning is a stressful event in the pig's life that contributes to intestinal and immune system dysfunctions. It is associated with a dietary change with inclusion of solid diet where mycotoxins can be present. A number of

approaches have been reported to control the adverse effects of mycotoxins in animal production systems (Weaver et al. 2013; Gallo et al. 2015). Among the proposed alternatives, probiotics are considered good candidates since they can improve intestinal health by stimulating the immune system and modulating gut microbiota (de Moreno de LeBlanc et al. 2008, Dogi et al. 2008), thereby improving animal health and productivity. For example, previous studies demonstrated that in a mouse model *Lactobacillus rhamnosus* RC007 decreased the gut inflammatory response induced by TNBS (Dogi et al. 2016). In this context, the aim of this study was to evaluate the beneficial effects of *L. rhamnosus* RC007 on the intestinal toxicity of DON in an *ex vivo* porcine model.

Materials and methods

Toxins. Purified DON was purchased from Sigma-Aldrich (Saint Louis, USA). This toxin was dissolved in water and stored at -20°C until use.

Bacterial strains. *L. rhamnosus* RC007 was previously isolated from maize silage and maintained at the National University of Río Cuarto Collection Centre (Córdoba, Argentina). This lactic acid bacteria (LAB) strain was identified from both the fermentation pattern (API 50 CHL test) and the 16S rRNA gene sequence. *L. rhamnosus* RC007 was grown at 37°C for 16 h without agitation in Man, Rogosa and Sharpe (MRS) broth (Sigma-Aldrich), under microaerophilic conditions.

Intestinal jejunal explants. Jejunal explants were obtained from 5 weeks old crossbred castrated male piglets as described previously (Lucioli et al. 2013; Pierron et al. 2016a). All animal experiments were performed at Toxalim animal facility under the guidelines of the French Minister of Agriculture (agreement APAFiS#6303_2016080314392462). Three authors (I.P.O., D.P., P.P.) have an official agreement with the French Veterinary Services permitting animal experimentation. Explants were treated i) with complete William's Medium E (Sigma, Saint Quentin Fallavier, France), control group, ii) exposed to 10⁹ CFU/mL *L. rhamnosus* in complete medium, iii) pre-treated with complete medium 1 h and then exposed to 10 µM DON in complete medium or iv) pre-incubated 1 h with 10⁹ CFU/mL *L. rhamnosus* and then exposed for 3 hours to 10 µM DON in complete medium. The explants were incubated at 39°C.

Histological assessment. For histological assessment the explants were treated 3 h before the fixation of the jejunal explants with 10% formalin for 24 h. Then, the tissues were dehydrated and embedded in paraffin according to standard histological procedures. Sections of 5 µm were stained with haematoxylin and eosin (Sigma-Aldrich) for histopathological assessment and intestinal morphometry (villi length). Histological findings were evaluated based on histological parameters and the severity of lesions described in the Table 1 of the Electronic Supplementary Material. Images were acquired with a Leica DMRB microscope. Analyses were performed using a MOTIC Image Plus 2.0 MLw image analysis system.

Intestinal permeability. *Ex vivo* paracellular and transcellular permeability were evaluated in jejunal explants after 3 h treatment. Two jejunal fragments for each animal were mounted in a Ussing chamber (Easy Mount, Physiologic Instruments), exposing a surface area measuring 0.1 cm². The specimens were bathed on each side with oxygenated thermostated Krebs solution (Sigma) and after equilibration, fluorescein sodium salt (FSS, 376 Da, Sigma-Aldrich) as a marker of paracellular permeability and horseradish peroxidase (HRP, 44kDa, Sigma Aldrich) as a marker of transcellular permeability were added in mucosal compartment at 40µg/mL and 0.4 mg/mL concentrations, respectively. Epithelial permeability to FSS was determined by measuring the fluorescence intensity 485 nm/525 nm using an automatic Infinite M200 microplate reader (Tecan). Epithelial permeability to intact HRP activity was assessed by an enzymatic assay measuring HRP activity with TMB substrate using a Tecan. Permeability was calculated as a ratio of the flux to the initial concentration, as previously described.

Gene expression analysis by RT-qPCR. For the gene expression analysis, jejunal explants were treated for 4 h and stored at -80°C before RNA extraction. Total RNAs were extracted in lysing matrix D tubes (MP Biomedicals, Illkirch, France) containing guanidine thiocyanate-acid phenol (Eurobio). The quantity of these RNAs was assessed (Nanodrop). Reverse transcription and RT-qPCR steps were performed as already described (Alassane-Kpembé et al. 2017, Pierron et al. 2016b). Primers are indicated in Table 1. Amplification efficiency and initial fluorescence were determined by the ΔCt method. Obtained values were normalized using two reference genes, ribosomal protein L32 (RPL32) and cyclophilin A. Expression levels of mRNA were expressed relative to the mean of the control.

Immunoblotting. Expression of the phosphorylated MAP Kinases p38 and p44/p42 and of the junction proteins were assessed on piglet jejunal explants by immunoblotting as previously described (Meissonnier et al. 2008; Pierron et al. 2016a). Explants were treated for 30 mins i) with complete medium (control), ii) exposed with 10^9 CFU/mL *L. rhamnosus* in complete medium iii) treated with 10 μ M DON in complete medium or iv) pre-incubated 1 h with 10^9 UFC/mL *L. rhamnosus* and then exposed for 30 min to 10 μ M DON in complete medium. Proteins were extracted, quantified and separated by SDS-PAGE. For the expression of MAPKinase, the membranes were probed with rabbit antibodies (Cell Signaling Technology, Danvers, USA) specific for phospho-p42/p44 or phospho-p38 diluted at 1:500 or p42/p44 and p38 diluted at 1:1000 overnight at 4°C. For the expression of junction proteins, mouse or rabbit antibodies specific for ZO-1, Claudin-2, Claudin-3 (Invitrogen, Camarillo, USA), JAM-A, Claudin-2 (Santa Cruz, Dallas, USA), and E-Cadherin (Cell Signaling Technology,) diluted at 1:250 or 1:500 (E-Cadherin) were used. After washing, the membranes were incubated with 1:10000 CFTM770 goat anti-rabbit IgG (Biotium, Hayward, USA) 1 h for the detection. Antibody detection was performed using an Odyssey Infrared Imaging Scanner (Li-Cor Science Tec, les Ulis, France) with the 770 nm channel. The expression of the proteins was estimated after normalization with the non-phosphorylated protein signal or β -actin.

Deoxynivalenol adsorption and degradation in vitro. To test the ability of *L. rhamnosus* RC007 to adsorb DON *in vitro*, a 24 h culture was obtained inoculating 15 mL of MRS broth and incubating in microaerofilia with 5% CO₂ and 37°C. After incubation 1 mL aliquots containing 10^9 CFU/mL were transferred to sterile microtubes, centrifuged at 3000 rpm for 10 min and supernatants were removed. Pellets were resuspended in 900 μ L sterile phosphate buffer saline (PBS) and added 200 μ L of a 52.90 ng/mL DON solution. Tubes were incubated for 30, 60, 120 and 180 min at 37°C in triplicates. After incubation, the tubes were centrifuged and DON concentration in the supernatants was quantified by HPLC according to Pascale et al. (2014) with some modifications. Briefly, supernatants containing unbound DON were evaporated to dryness under N₂ flow at 50°C and residues were redissolved in 300 μ L methanol:water (15:85, v/v). Fifty μ L aliquots were injected in a Waters e2695 Separations Module (Waters Corp., Milford, MA, USA) connected to a Waters 2998 Photodiode Array Detector (Waters Corp.) set at 220 nm. The column was a C18 RP Phenomenex Luna (150 \times 4.60mm, 5 μ m) (Phenomenex Inc., Torrance, CA, USA). The mobile phase was composed by 95% A: methanol:water (15:85, v/v) and 5% B: acetonitrile:methanol (1:1, v/v) + 0.5% acetic acid, pumped at 1.2 mL/min. A calibration curve was performed injecting 50 μ L of DON standard solutions equivalent to 10, 25, 50, 100 and 200 ng DON. Controls tubes containing DON+PBS incubated at the same conditions were also included.

DON degradation by *L. rhamnosus* RC007 enzymes was tested using a cell-free culture supernatant. A 24 h culture was centrifuged at 3000 rpm for 10 min and then filtered through a 0.22 μ m Millipore cellulose acetate membrane. Eight-hundred μ L aliquots were transferred to microtubes in triplicates and added 200 μ L of 52.90 ng/mL DON solution. Tubes were incubated for 48 h at 37°C in the darkness and DON concentration was quantified by HPLC as previously described. Controls tubes containing DON and MRS broth without *L. rhamnosus* were included.

Statistical analysis. All statistical analyses were performed using GraphPad Prism 4.0. Differences between the experimental groups were evaluated using one-way analysis of variance (ANOVA) followed by Bonferroni post-test (which allows comparison of all pair of groups). All data were expressed as mean \pm standard error of the mean (SEM). A p value below 0.05 was considered as significant.

Results

***L. rhamnosus* RC007 reduced the histological and alterations induced by DON in jejunal explants.**

In order to investigate the ability of *L. rhamnosus* to counteract the effect of DON on intestinal tissue, explants were kept as control, treated with DON, *L. rhamnosus* or both. Control explants as well as explants treated with *L. rhamnosus* displayed normal villi lined with columnar enterocytes and microvilli at the top of intestinal cells (Fig. 1A, i and ii, B-C). After 3 h incubation with 10 μ M DON, explants displayed severe histological alterations such as multifocal to diffuse villi atrophy, necrosis, loss of apical enterocytes and loss of microvilli on epithelial cells (Fig. 1A, iii, B-C). Conversely, jejunal explants exposed to *L. rhamnosus* prior to DON treatment showed normal villi length (Fig. 1B-C), columnar intestinal epithelial cells with microvilli, without villi fusion and atrophy (Fig. 1A, iv).

***L. rhamnosus* RC007 reduced the paracellular permeability induced by DON *ex vivo* on jejunal explants without altering the junction proteins.**

To continue the investigations on the intestinal barrier function, transcellular and paracellular permeability was measured on jejunal explants mounted in Ussing chambers. Transcellular permeability was assessed by measuring the intact horseradish peroxidase (44 KDa) activity and paracellular permeability (< 4KDa) was

determined by measuring the passage of fluorescein salt sodium (376 Da) (Fig. 2). Exposure to 10 μ M DON did not increase significantly the transcellular permeability to horseradish peroxidase in piglet jejunal explants as compared to control group or groups treated with *L. rhamnosus* (Fig. 2A). However, exposure to 10 μ M DON significantly increased the paracellular permeability (17.59 ± 4.9 FSS cm/s 10^{-7} in DON-treated explants versus 7.93 ± 1.75 FSS cm/s 10^{-7} in control group; $p < 0.001$). By contrast, no significant increase of paracellular permeability to fluorescein salt sodium was observed in jejunal explants treated with *L. rhamnosus* and 10 μ M DON as compared to control group but a significant decrease was observed in the group treated with *L. rhamnosus* and DON (12.28 ± 5.23 FSS cm/s 10^{-7} in *L. rhamnosus* and DON-treated explant versus 17.59 ± 4.9 FSS cm/s 10^{-7} in DON-treated explants, $p < 0.05$) (Fig. 2B).

The next step was to characterize the effect of the probiotic strain *L. rhamnosus* on the expression of junction proteins in jejunal explants treated or not with DON (Table 2). Exposure to *L. rhamnosus*, DON and the co-exposure to *L. rhamnosus* and DON both did not affect the expressions of the 6 junction proteins tested (E-cadherin, ZO-1, JAM, Claudin-2, -3 and -4) in jejunal explants. This lack of effect was observed both at the mRNA and the protein levels.

***L. rhamnosus* RC007 reduced the expression of pro-inflammatory cytokines induced by DON.**

To deeper investigate the protective effect of *L. rhamnosus*, the expression of several pro-inflammatory genes was assessed by qPCR (Fig. 3). As expected, DON increased significantly the expression of IL-1 β , TNF α , IL-22 and IL-8 pro-inflammatory cytokine genes as compared to control group. An increase of the chemokine gene expression CCL20 and the anti-inflammatory cytokine IL-10 was also observed. By contrast, treatment of jejunal explants with *L. rhamnosus* and DON did not induce an increase in the expression of inflammatory genes.

***L. rhamnosus* RC007 reduced the phosphorylation of MAP Kinases p42/p44 and p38 induced by DON.**

The ability of *L. rhamnosus* to counteract the effects of DON on the activation of the MAP Kinase was then examined. After 30 min of exposure to 10 μ M of DON, MAP Kinases were activated in jejunal explants (Fig. 4). DON significantly increased phosphorylated p42/p44 and phosphorylated p38 compared to control condition. By contrast, pre-exposure of jejunal explants to *L. rhamnosus*, did not activate these MAP kinases, even in the presence of DON.

Deoxynivalenol adsorption and degradation in vitro.

When the ability of *L. rhamnosus* RC007 to adsorb DON was tested, no significant effect was observed at any of time point. Of note, cell-free supernatant from *L. rhamnosus* RC007 culture was able to degrade 13% DON when incubated for 48 h at 37°C (Table 3).

Discussion

The epithelial barrier of the gastrointestinal tract is the initial line of defense against orally ingested bacterial and viral pathogens, as well as food- and feed-derived toxins. After ingestion, DON induces several adverse effects including an alteration of gut integrity and the induction of an inflammatory response (Akbari et al. 2014; Pinton and Oswald 2014). One of the many strategies to counteract the harmful effect of mycotoxins is the addition of probiotic to animal diet. Probiotics added in feed improve performance, promote metabolic processes of digestion and nutrient utilization, and modulate intestinal barrier and immune responses (Hardy et al. 2013). Nevertheless, the magnitude of the effect seems to be strain dependent. In the present work, the effects of the probiotic strain *L. rhamnosus* RC007 on DON intestinal toxicity using a jejunal explants model were investigated. In the context of reducing the number of experimental animals, intestinal explants represent a powerful model and have been introduced as a model to test intestinal integrity since allows to preserving normal histological structure *in vitro* (Nietfeld et al. 1991). This model was used to investigate the effects of food contaminants (Lucioli et al. 2013; Alassane-Kpembi et al. 2017). In the present study, as previously observed, the treatment of jejunal explants with 10 μ M DON caused important changes on the intestinal barrier function (Lucioli et al. 2013; Ghareeb et al. 2015). The mycotoxin not only altered the intestinal histomorphology but also increased the intestinal permeability, mainly at the paracellular level. The observed effects of DON on the impairment of the intestinal morphology may have consequences on absorption and nutrient intake by intestinal epithelial cells. Consequently, energy and nutrient uptake can be adversely affected leading to growth deficiencies in animals. Intestinal epithelial cells form a monolayer that constitutes a dynamic and selective barrier, and mediates the transport of molecules in two ways, either across the cells (i.e., the transcellular pathway) or between them (i.e., the paracellular pathway). Effects in the paracellular pathway suggest an adverse effect on tight junctions and could result in an increased translocation of luminal antigens and pathogens and an excessive activation of the immune system (Grenier and Applegate 2013).

The *Lactobacillus* concentration used in this study correspond to a typical dose of probiotic administration in human and animals (Yang et al. 2015), and this dose was previously demonstrated *in vivo* to produce beneficial

effects in mice (Dogi et al., 2016). The dose of 10 μ M DON was chosen as it causes important changes on the intestinal barrier function (Lucioli et al. 2013; Ghareeb et al. 2015; Pierron et al. 2016b). This concentration is realistic when considering human and animal exposure to DON. In Human gut, concentrations of 0.16–2 μ g DON /mL (0.5–7 μ M) can be considered as realistic. The lower concentration value corresponds to the mean estimated daily intake of French adult consumers on a chronic basis. The higher concentration value simulates level that can be reached after the consumption of heavily contaminated food, as can be occasionally encountered (Alassane-Kpembi et al. 2013). Animal, especially pigs can be exposed higher concentrations of DON. Assuming that DON is ingested in one meal, diluted in 1 L of gastrointestinal fluid and is totally bio accessible, the in vitro concentration of 10 μ M used in this study correspond to feed contaminated with 3mg DON/Kg (Pinton et al. 2009). In a recent scientific opinion, EFSA reported levels of DON in feed grains up to 9.5 mg/kg (EFSA, 2017).

The pre-incubation of explants with *L. rhamnosus* was able to counteract the adverse effects of DON on the intestine as seen by the restored villi length, the columnar intestinal epithelial cells with microvilli and the restored paracellular activity. These results indicate a protective effect of this bacterium. It is believed that a probiotic improves the metabolic processes due to improved development of the gut and increased microvilli height leading to the enlargement of the microvilli's absorptive surface and enables the optimal utilization of nutrients (Ezema 2013). A previous study demonstrated a beneficial effect of *L. rhamnosus* RC007 on TNBS-induced colitis with less macroscopic and histologic damages in the large intestine of mice (Dogi et al. 2016). Other studies have reported a beneficial effect of probiotics on intestinal paracellular permeability in different chemically-induced colitis models (Osman et al. 2008; Southcott et al. 2008).

The health-promoting properties of probiotics are multiple and include their capacity to activate/modulate the host immune system. Following consumption of probiotic products, the interaction of these bacteria with intestinal enterocytes initiates a host response, since intestinal cells produce various immunomodulatory molecules when stimulated by bacteria in a strain-dependent manner (Galdeano et al. 2007; de Moreno de LeBlanc et al. 2008; Dogi et al. 2008, 2010). In the present study, we observed, as was previously described, a significant expression of pro-inflammatory cytokines in DON treated intestinal explants (Pierron et al. 2016a; Cano et al. 2013). The pre-incubation of the explants with *L. rhamnosus* RC007 was able to counteract this inflammatory effect. Immunomodulatory properties of this strain were already described; it stimulates the immune system in a healthy host and modulates the inflammatory immune response in a mice model of TNBS colitis (Dogi et al. 2016).

Mitogen-activated protein kinases (MAPKs) mediate a wide variety of cellular behaviors in response to extracellular stimuli (Widman et al. 1999). The p38 MAP kinases, has been implicated in several complex biologic processes, such as cell proliferation, cell differentiation, cell death, cell migration and invasion (Koul et al. 2013). The p44/42 ERK is of particular interest, because it can be involved in intestinal epithelial cell morphology and in the structure of tight junctions. Upon DON exposure, a ribotoxic stress response is induced that results in the activation of MAPKs. This mediates apoptosis, aberrant up-regulation of pro-inflammatory cytokines and chemokines, the disruption of the intestinal barrier and an alteration of the tight junction network (Pestka 2010; Pan et al. 2013; Pinton et al. 2015; Springler et al. 2016). The pre incubation with *L. rhamnosus* RC007 was able to inhibit the signaling pathway and to decrease MAPKs activation. Numerous evidences demonstrate that probiotics bacteria communicate with the host by modulating key signaling pathways, such as NF κ B and MAPK, to either enhance or suppress activation and influence downstream pathways (Kelly et al. 2004; Resta-Lenert et al. 2006; Kim et al. 2008; Watanabe et al. 2009). Similar mode of action was demonstrated with probiotic yeast (Chang et al. 2017).

Barrier property of the intestine is achieved by intercellular junctions that include apical tight junction proteins, such as claudins, ZO and JAM, and subjacent adherens junctions such as E-cadherin (Groschwitz and Hogan, 2009). The protective effect of *L. rhamnosus* was not mediated by these molecules as demonstrated by the absence of their regulation whatever the treatment. Previous studies have observed an alteration of claudin, cadherin and ZO-1 in rats or pigs fed DON contaminated diet as well as in intestinal cells treated with the mycotoxin (Pinton et al. 2012, Pinton et al 2014, Akbari et al. 2014). In the present study, we did not observe any of these effects in explants treated with of DON. The difference might be due to reduced exposure length, 4 hours, in explants when compared to feeding trials or prolonged exposure of intestinal epithelial cells. Alternatively, as described for other mycotoxins, DON might only relocalize the junction, which could then be restored by *L. rhamnosus* (Lambert et al. 2007; Menningen et al. 2009). The western-blot does not allow investigating this hypothesis.

The mechanism by which *L. rhamnosus* transduces its health benefits to the host is still under study. The present paper indicates that this strain does not absorb DON. Moreover the minimal ability of this strain to degrade DON is too low to explain the observed effect. Previous studies reported microbial transformation of DON into DOM-1 in several animal species as well as in humans (Döll and Dänicke 2004; Turner et al. 2010). In the present study, the modified form of DON obtained after *L. rhamnosus* degradation was not determined. Our data suggest

that *L. rhamnosus* interact with MAPKs proteins helping to maintain normal function of the gut mucosa, not only enhancing barrier function but also modulating the gut immune response, since MAPKs are involved in regulation of multiple biological processes including development, apoptosis and immunity (Yan and Polk 2002; Jijon et al. 2004; Joshi and Plataniias 2012). DON is known to alter the intestinal microbiota (Wache et al., 2008; Robert et al., 2017). Although it was not the objective of this study, we can hypothesize that *L. rhamnosus* restores the gut microbiota, known for its importance for human and animal health.

In conclusion, our results demonstrated that *L. rhamnosus* counteracts the intestinal toxic effects of DON and helps to maintain a healthy gastrointestinal tract. This is crucial as it ensures that nutrients are absorbed at an optimum rate, it provides efficient protection against pathogens, and maintains the indigenous microbiota in adequate numbers and confined to their natural niches.

Conflict of Interest. The authors declare that they have no conflict of interest.

References

- Akbari P, Braber S, Gremmels H, Koelink PJ, Verheijden KAT, Garssen J, Fink-Gremmels J (2014) Deoxynivalenol: A trigger for intestinal integrity breakdown. *FASEB J* 28:2414-2429. doi: 10.1096/fj.13-238717.
- Alassane-Kpembi I, Kolf-Clauw M, Gauthier T, Abrami R, Abiola FA, Oswald IP, Puel O (2013) New insight into mycotoxin mixtures: the toxicity of low doses of Type B trichothecenes against intestinal epithelial cells is synergistic. *Tox. Appl. Pharmacol.* 272:191-198. doi:10.1016/j.taap.2013.05.023
- Alassane-Kpembi I, Puel O, Pinton P, Cossalter AM, Chou TC, Oswald IP (2017) Co-exposure to low doses of the food contaminants Deoxynivalenol and Nivalenol has a synergistic inflammatory effect on intestinal explants. *Arch Toxicol.* 91: 2677-87. doi:10.1007/s00204-016-1902-9.
- Cano P, Seeboth J, Meurens F, Cognie J, Abrami R, Oswald IP, Guzylack-Piriou L (2013) Deoxynivalenol as a new factor in the persistence of intestinal inflammatory diseases: an emerging hypothesis through possible modulation of Th17-mediated response *PlosOne.* 8:e53647. doi: 10.1371/journal.pone.0053647.
- Chang C, Wang K, Zhou SN, Wang XD, Wu JE (2017) Protective Effect of *Saccharomyces boulardii* on Deoxynivalenol-Induced Injury of Porcine Macrophage via Attenuating p38 MAPK Signal Pathway. *Appl Biochem Biotechnol.* 182:411-427. doi:10.1007/s12010-016-2335-x.
- Dänicke S, Döll S (2010) A probiotic feed additive containing spores of *Bacillus subtilis* and *B. licheniformis* does not prevent absorption and toxic effects of the *Fusarium* toxin deoxynivalenol in piglets. *Food Chem Toxicol* 48:152-8. doi: 10.1016/j.fct.2009.09.032.
- de Moreno de LeBlanc A, Chaves S, Carmuega E, Weill R, Antoine J, Perdígón G (2008) Effect of long-term continuous consumption of fermented milk containing probiotic bacteria on mucosal immunity and the activity of peritoneal macrophages. *Immunobiol* 213:97-108. doi: 10.1016/j.imbio.2007.07.002.
- Dogi C, Weill F, Perdígón G (2010) Immune response of non-pathogenic Gram (+) and Gram (-) bacteria in inductive sites of the intestinal mucosa. Study of the pathway of signaling involved. *Immunobiol* 215:60-9. doi: 10.1016/j.imbio.2009.01.005.
- Dogi C, Garcia G, de Moreno de LeBlanc A, Greco C, Cavaglieri L (2016) *Lactobacillus rhamnosus* RC007 intended for feed additive: Immunostimulatory properties and ameliorating effects on TNBS-induced colitis. *Benef Microbes* 6:1-10. doi: 10.3920/BM2015.0147.
- Dogi C, Maldonado Galdeano C, Perdígón G. (2008) Gut immune stimulation by non pathogenic Gram (+) and Gram (-) bacteria. Comparison with a probiotic strain. *Cytokine* 41:223-31. doi: 10.1016/j.cyto.2007.11.014.
- Döll S, Dänicke S (2004). In vivo detoxification of *Fusarium* toxins. *Arch Anim Nutr* 58:419-441. doi: 10.1080/00039420400020066.
- EFSA CONTAM Panel (EFSA Panel on Contaminants in the Food Chain), Knutsen HK, Alexander J, Barregård L, Bignami M, Bruschweiler B, Ceccatelli S, Cottrill B, Dinovi M, Grasl-Kraupp B, Hogstrand C, Hoogenboom LR, Nebbia CS, Oswald IP, Petersen A, Rose M, Roudot A-C, Schwerdtle T, Vleminckx C, Vollmer G, Wallace H, De Saeger S, Eriksen GS, Farmer P, Fremy JM, Gong YY, Meyer K, Naegeli H, Parent-Massin D, Rietjens I, van Egmond H, Altieri A, Eskola M, Gergelova P, Ramos Bordajandi L, Benkova B, Dorr B, Gkrillas A, Gustavsson N, van Manen M, Edler L (2017) Scientific Opinion on the risks to human and animal health related to the presence of deoxynivalenol and its acetylated and modified forms in food and feed. *EFSA J* 15:4718. doi:10.2903/j.efsa.2017.4718
- Ewaschuk J, Endersby R, Thiel D, Diaz H, Backer J, Ma M, Churchill T, Madsen K (2007) Probiotic bacteria prevent hepatic damage and maintain colonic barrier function in a mouse model of sepsis. *Hepatology* 46:841-50. doi: 10.1002/hep.21750.
- Ezema C (2013) Probiotics in animal production: A review. *J Vet Med Anim Health* 5:308-316. doi: 10.5897/JVMAH2013.0201.

- Galdeano CM, de Moreno de LeBlanc A, Vinderola G, Bonet ME, Perdigon G (2007) Proposed model: mechanisms of immunomodulation induced by probiotic bacteria. *Clin Vaccine Immunol* 14:485-92. doi: 10.1128/CVI.00406-06.
- Gallo A, Giuberti G, Frisvad JC, Bertuzzi T, Nielsen KF (2015) Review on mycotoxin issues in ruminants: occurrence in forages, effects of mycotoxin ingestion on health status and animal performance and practical strategies to counteract their negative effects. *Toxins* 7: 3057-3111. doi:10.3390/toxins7083057.
- Ghareeb K, Awad WA, Bohm J, Zebeli Q (2015) Impacts of the feed contaminant Deoxynivalenol on the intestine of monogastric animals: poultry and swine. *J Appl Toxicol* 35:327-337. doi: 10.1002/jat.3083.
- Grenier B, Bracarense AP, Schwartz HE, Trumel C, Cossalter AM, Schatzmayr G, Kolf-Clauw M, Moll WD, Oswald IP (2012). The low intestinal and hepatic toxicity of hydrolyzed fumonisin B₁ correlates with its inability to alter the metabolism of sphingolipids. *Biochem Pharmacol* 83:1465-1473. doi: 10.1016/j.bcp.2012.02.007.
- Grenier B, Applegate TJ (2013) Modulation of intestinal functions following mycotoxin ingestion: Meta-analysis of published experiments in animals. *Toxins* 5:396-430. doi: 10.3390/toxins5020396.
- Groschwitz KR, Hogan SP (2009) Intestinal barrier function: molecular regulation and disease pathogenesis. *J Allergy Clin Immunol*. 124:3-20. doi: 10.1016/j.jaci.2009.05.038.
- Hardy H, Harris J, Lyon E, Beal J, Foey AD (2013) Probiotics, prebiotics and immunomodulation of gut mucosal defences: homeostasis and immunopathology. *Nutrients* 5:1869-1912. doi: 10.3390/nu5061869.
- Jijon H, Backer J, Diaz H, Yeung H, Thiel D, McKaigney C, et al. (2004) DNA from probiotic bacteria modulates murine and human epithelial and immune function. *Gastroenterology* 126:1358-73. doi:10.1053/j.gastro.2004.02.003.
- Joshi S, Plataniias LC (2012) Mnk kinases in cytokine signaling and regulation of cytokine responses. *Biomol concepts* 3:127-139. doi: 10.1515/bmc-2011-2000.
- Kelly D, Campbell JI, King TP, Grant G, Jansson EA, Coutts AG, Pettersson S, Conway S (2004) Commensal anaerobic gut bacteria attenuate inflammation by regulating nuclear-cytoplasmic shuttling of PPAR-g and RelA. *Nat Immunol* 5:104-12. doi: 10.1038/ni1018.
- Kim HG, Lee SY, Kim NR, Ko MY, Lee JM, Yi TH, et al. (2008) Inhibitory effects of *Lactobacillus plantarum* lipoteichoic acid (LTA) on *Staphylococcus aureus* LTA-induced tumor necrosis factor- α production. *J Microbiol Biotechnol* 18:1191-6.
- Koul HK, Pal M, Koul S (2013) Role of p38 MAP kinase signal transduction in solid tumors. *Genes Cancer* 4:342-359. doi: 10.1177/1947601913507951.
- Lambert D, Padfield PJ, McLaughlin J, Cannell S, O'Neill CA, (2007) Ochratoxin A displaces claudins from detergent resistant membrane microdomains. *Biochem Biophys Res Commun*. 358:632-6. doi: 10.1016/j.bbrc.2007.04.180
- Lucioli J, Pinton P, Callu P, Laffitte J, Grosjean F, Kolf-Clauw M, Oswald IP, Bracarense AP (2013) The food contaminant deoxynivalenol activates the mitogen activated protein kinases in the intestine: comparison of in vivo and ex vivo models. *Toxicol*. 66: 31-36. doi: 10.1016/j.toxicol.2013.01.024.
- Mao Y, Nobaek S, Kasravi B, Adawi D, Stenram U, Molin G, Jeppsson B. (1996) The effects of *Lactobacillus* strains and oat fiber on methotrexate-induced enterocolitis in the rats. *Gastroenterology* 111:334-344. doi: 10.1053/gast.1996.v111.pm8690198
- Maresca (2013) From the gut to the brain: journey and pathophysiological effects of the food-associated trichothecene mycotoxin deoxynivalenol. *Toxins*. 5:784-820. doi: 10.3390/toxins5040784.
- Meissonnier GM, Laffitte J, Raymond I, Benoit E, Cossalter AM, Pinton P, Bertin G, Oswald IP, Galtier P (2008) Subclinical doses of T-2 toxin impair acquired immune response and liver cytochrome P450 in pigs. *Toxicology* 247:46-54. doi: 10.1016/j.tox.2008.02.003.
- Menningen R, Nolte K, Rijken E, Utech M, Loeffler B, Senninger N, Bruewer M (2009) Probiotic mixture VSL#3 protects the epithelial barrier by maintaining tight junction protein expression and preventing apoptosis in a murine model of colitis. *Am J Physiol Gastrointest Liver Physiol* 296,G1140-G1149. doi: 10.1152/ajpgi.90534.2008.
- Mercenier A, Pavan S, Pot B (2003) Probiotics as biotherapeutic agents: present knowledge and future prospects. *Curr Pharm Des* 9:175-191.
- Nietfeld JC, Tyler DE, Harrison LR, Cole JR, Latimer KS, Crowell WA (1991) Culture and morphologic features of small intestinal mucosal explants from weaned pigs. *Am J Vet Res* 52:1142-1146.
- Osman N, Adawi D, Ahrné S, Jeppsson B, Molin G (2008) Probiotics and blueberry attenuate the severity of dextran sulfate sodium (DSS)-induced colitis. *Dig Dis Sci* 53:2464-2473. doi: 10.1007/s10620-007-0174-x.
- Pan X, Whitten DA, Wu M, Chan C, Wilkerson CG, Pestka JJ (2013) Early phosphoproteomic changes in the mouse spleen during deoxynivalenol-induced ribotoxic stress. *Toxicol Sci* 135:129-143. doi:10.1093/toxsci/kft145.

- Pascale M, Panzarini G, Powers S, Visconti A (2014) Determination of Deoxynivalenol and Nivalenol in Wheat by Ultra-Performance Liquid Chromatography/Photodiode-Array. *Food Anal Method* 7:555-562. doi:10.1007/s12161-013-9653-1.
- Payros D, Alassane-Kpembi I, Pierron A, Loiseau N, Pinton P, Oswald IP (2016) Toxicology of deoxynivalenol and its acetylated and modified forms. *Arch Toxicol* 90:2931-2957. doi: 10.1007/s00204-016-1826-4.
- Pestka JJ, Smolinski AT (2005) Deoxynivalenol: Toxicology and potential effects on humans. *J. Toxicol. Environ. Heal.* 8:39-69. doi: 10.1080/10937400590889458.
- Pierron A, Mimoun S, Murate LS, Loiseau N, Lippi Y, Bracarense APFL, Schatzmayr G, He J, Zhou T, Moll WD, Oswald IP (2016a) Microbial biotransformation of DON: molecular basis for reduced toxicity. *Sci Rep.* 6:29105. doi: 10.1038/srep29105.
- Pierron A, Mimoun S, Murate LS, Loiseau N, Lippi Y, Bracarense APFL, Schatzmayr G, Berthiller F, Moll WD, Oswald IP (2016b) Intestinal toxicity of the masked mycotoxin deoxynivalenol-3- β -d-glucoside. *Arch. Toxicol.* 90:2037-2046. doi: 10.1007/s00204-015-1592-8.
- Pinton P, Graziani F, Pujol A, Nicoletti C, Paris O, Ernouf P, Di Pasquale E, Perrier J, Oswald IP, Maresca M (2015) Deoxynivalenol inhibits the expression by goblet cells of intestinal mucins through a PKR and MAP kinase dependent repression of the resistin-like molecule. *Mol Nutr Food Res* 59: 1076-1087. doi: 10.1002/mnfr.201500005.
- Pinton P, Oswald IP (2014) Effect of Deoxynivalenol and other Type B Trichothecenes on the Intestine: a review. *Toxins* 6:1615-43. doi: 10.3390/toxins6051615.
- Pinton P, Tsybulskyy D, Lucioli J, Laffitte J, Callu P, Lyazhri F, Grosjean F, Bracarense AP, Kolf-Clauw M, Oswald IP (2012) Toxicity of deoxynivalenol and its acetylated derivatives on the intestine: differential effects on morphology, barrier function, tight junctions proteins and MAPKinases. *Toxicol Sci* 130:180-90. doi: 10.1093/toxsci/kfs239.
- Pinton P, Nougayrede JP, del Rio JC, Moreno C, Marin D, Ferrier L, Bracarense AP, Kolf-Clauw M, Oswald IP (2009) The food contaminant, deoxynivalenol, decreases intestinal barrier function and reduces claudin expression. *Tox. Appl. Pharmacol.* 237:41-48. doi:10.1016/j.taap.2009.03.003
- Resta-Lenert S, Barrett KE (2006) Probiotics and commensals reverse TNF α - and IFN γ -induced dysfunction in human intestinal epithelial cells. *Gastroenterology* 130:731-46. doi: 10.1053/j.gastro.2005.12.015.
- Robert H, Payros D, Pinton P, Théodorou V, Mercier-Bonin M, Oswald IP (2017) Impact of mycotoxins on the intestine: are mucus and microbiota new targets? *J. Toxicol. Env. Health, Part B: Crit. Rev.* 20:249-275. doi: 10.1080/10937404.2017.1326071
- Southcott E, Tooley KL, Howart GS, Davidsson GP, Butler RN (2008) Yoghurts containing probiotics reduce disruption of the small intestinal barrier in methotrexate-treated rats. *Dig Dis Sci* 53:1837-41. doi: 10.1007/s10620-008-0275-1.
- Springler A, Hessenberger S, Schatzmayr G, Mayer E (2016) Early Activation of MAPK p44/42 Is Partially Involved in DON-Induced Disruption of the Intestinal Barrier Function and Tight Junction Network. *Toxins* 8:264. doi:10.3390/toxins8090264.
- Turner PC, Hopton RP, Lecluse Y, White KL, Fisher J, Lebailly P (2010) Determinants of urinary deoxynivalenol and de-epoxy deoxynivalenol in male farmers from Normandy, France. *J Agr Food Chem* 58:5206-12. doi: 10.1021/jf100892v.
- Waché Y, Valat C, Postollec G, Bougeard S, Burel C, Oswald IP, Fravalo P (2009) Impact of Deoxynivalenol on the Intestinal Microflora of Pigs. *Int J Mol Sci* 10: 1-17. doi:10.3390/ijms10010001
- Watanabe T, Nishio H, Tanigawa T, Yamagami H, Okazaki H, Watanabe K, et al. (2009) Probiotic *Lactobacillus casei* strain Shirota prevents indomethacin-induced small intestinal injury: involvement of lactic acid. *Am J Physiol Gastrointest Liver Physiol* 297:506-13. doi: 10.1152/ajpgi.90553.2008.
- Weaver AC, See MT, Hansen JA, Kim YB, De Souza AL, Middleton TF, Kim SW (2013) The use of feed additives to reduce the effects of aflatoxin and deoxynivalenol on pig growth, organ health and immune status during chronic exposure. *Toxins* 5:1261-1281. doi: 10.3390/toxins5071261.
- Widmann C, Gibson S, Jarpe MB, Johnson GL (1999) Mitogen-activated protein kinase: conservation of a three-kinase module from yeast to human. *Physiol Rev* 79:143-180.
- Yan F, Polk DB (2002) Probiotic bacterium prevents cytokine-induced apoptosis in intestinal epithelial cells. *J Biol Chem* 277:50959-65. doi: 10.1074/jbc.M207050200.
- Yang F, Hou C, Zeng X, Qiao S (2015) The Use of Lactic Acid Bacteria as a Probiotic in Swine Diets. *Pathogens* 4:34-45. doi:10.3390/pathogens4010034
- Zaki M (2012) Mycotoxins in animals: Occurrence, effects, prevention and management. *J Toxicol Environ Health Sci* 4:13-28. doi: 10.5897/JTEHS11.072.

Table 1.Primer sequences used for RT-qPCR analysis (F: Forward ; R: Reverse)

Gene Symbol	Gene name	Primer sequence	Reference
Cyclo A	Cyclophilin A	F : CCCACCGTCTTCTTCGACAT	NM_214353
		R : TCTGCTGTCTTTGGAACCTTGTCT	Pinton et al. 2015
RPL32	Ribosomal Protein 32	F: AGTTCATCCGGCACCAGTCA	NM_001001636
		R: GAACCTTCTCCGCACCCTGT	Alassane-Kpembé et al. 2017
IL-22	Interleukin 22	F: AAGCAGGTCCTGAACTTCAC	AY937228
		R: CACCCTTAATACGGCATTGG	Cano et al. 2013
CCL20/MIP3 α	C-C Chemokine Ligand 20	F : GCTCCTGGCTGCTTTGATGTC	NM_001024589
		R : CATTGGCGAGCTGCTGTGTG	Cano et al. 2013
IL-1 β	Interleukin 1 beta	F: ATGCTGAAGGCTCTCCACCTC	NM_214055
		R: TTGTTGCTATCATCTCCTTGCAC	Pierron et al. 2016
IL-8	Interleukin 8	F: GCTCTCTGTGAGGCTGCAGTTC	NM_213867
		R: AAGGTGTGGAATGCGTATTTATGC	Grenier et al. 2012
IL-10	Interleukin 10	F : GGCCAGTGAAGAGTTTCTTTC	NM_214041
		R : CAACAAGTCGCCCATCTGGT	Cano et al. 2013
TNF- α	Tumor Necrosis Factor alpha	F : ACTGCACTTCGAGGTTATCGG	NM_214022
		R : GGCGACGGGCTTATCTGA	Grenier et al. 2012
ZO-1	Zonula Occludens 1	F:ATAACATCAGCACAGTGCCTAAAGC	ENSG00000104067
		R : GTTGCTGTAAACACGCCTCG	Current article
Claudin-2	Claudin 2	F : CAGCATGAAATTTGAGATCGGA	ENSG00000165376
		R :GAGGAAATGATGCCCAAGTAGAGA	Current article
Claudin-3	Claudin 3	F : CTGCTCTGCTGCTCGTGCCC	ENSG00000165215
		R :TCATACGTAGTCCTTGCGGTCGTAG	Current article
Claudin-4	Claudin 4	F : CTGCTTTGCTGCAACTGCC	OTTHUMG00000023425
		R:TCAACGGTAGCACCTTACACGTAGT	Pinton et al. 2012
E-Cadherin	E cadherin	F : ACCACCGCCATCAGGACTC	ENSSSCG00000006369
		R : TGGGAGCTGGGAAACGTG	Current article
JAM	Junctional Adhesion Molecule A	F : CGTGCCTTCATCAACTCTTCCTATA	ENSSSCG00000025652
		R:CACAAGTGTAATCTCCAGCATCAGA	Current article

Table 2. Effect of DON and *L. rhamnosus* on the expressions of the genes and proteins of tight junctions in jejunal explants.

	Jejunal treatment			
	Control	<i>L. rhamnosus</i>	DON	<i>L. rhamnosus</i> + DON
Gene expression (2ΔCt)				
Claudin -2	0.09 \pm 0.01 ^a	0.17 \pm 0.04 ^{ab}	0.13 \pm 0.02 ^{ab}	0.25 \pm 0.04 ^b
Claudin -3	0.02 \pm 0.004 ^a	0.06 \pm 0.01 ^{ab}	0.02 \pm 0.005 ^a	0.07 \pm 0.02 ^b
Claudin -4	0.08 \pm 0.02 ^a	0.11 \pm 0.02 ^a	0.13 \pm 0.02 ^a	0.14 \pm 0.02 ^a
E-cadherin	1.7 \pm 0.7 ^a	1.5 \pm 0.32 ^a	2.0 \pm 0.77 ^a	1.32 \pm 0.56 ^a
ZO-1	0.02 \pm 0.005 ^a	0.02 \pm 0.002 ^a	0.02 \pm 0.005 ^a	0.02 \pm 0.004 ^a
JAM	0.10 \pm 0.008 ^{ab}	0.06 \pm 0.01 ^b	0.13 \pm 0.01 ^a	0.08 \pm 0.01 ^b
Protein expression (A. U.)				
Claudin -2	0.21 \pm 0.02 ^a	0.24 \pm 0.04 ^a	0.22 \pm 0.02 ^a	0.19 \pm 0.02 ^a
Claudin -3	0.30 \pm 0.05 ^{ab}	0.28 \pm 0.06 ^{ab}	0.47 \pm 0.08 ^a	0.19 \pm 0.05 ^b
Claudin -4	4.01 \pm 0.74 ^a	2.61 \pm 0.34 ^a	3.21 \pm 0.40 ^a	2.45 \pm 0.40 ^a
E-cadherin	0.07 \pm 0.01 ^a	0.06 \pm 0.01 ^a	0.08 \pm 0.02 ^a	0.04 \pm 0.01 ^a
ZO-1	0.04 \pm 0.005 ^a	0.03 \pm 0.01 ^a	0.03 \pm 0.004 ^a	0.02 \pm 0.01 ^a
JAM	0.04 \pm 0.01 ^a	0.05 \pm 0.02 ^a	0.05 \pm 0.01 ^a	0.04 \pm 0.01 ^a

Data are mean \pm SEM. Within a line, values not sharing a common superscript are significantly different (p<0.05)

Table 3. Biological degradation of DON by *Lactobacillus rhamnosus* RC007

Treatment	Final DON level (ng)	% of degradation
Control	4691.07 ± 25.6 ^a	0
<i>L. rhamnosus</i> RC007	4065.84 ± 26.16 ^b	13.33

Deoxynivalenol degradation was tested using a cell-free culture supernatant. DON concentration was quantified by HPLC.

Values with different letter are significantly different according to Fisher's protected LSD test ($p < 0.05$).




Fig. 1. Effects of *L. rhamnosus* and DON on intestinal explants. (A) Morphology, (B) lesional score and (C) villi length. Jejunal explants were exposed i) with complete medium (control), ii) with 10^9 CFU/mL *L. rhamnosus* in complete medium, iii) pre-treated with complete medium 1 h and then exposed to $10 \mu\text{M}$ DON in complete medium or iv) pre-incubated 1 h with 10^9 CFU/mL *L. rhamnosus* and then exposed 3 h to $10 \mu\text{M}$ DON in complete medium. Yellow bars represented $10 \mu\text{m}$. Results represent mean and SEM of explants from 6 animals. One-way ANOVA with Bonferroni's multiple comparisons.

Figure 2.




Fig. 2. Effects of *L. rhamnosus* and DON on intestinal transcellular (A) and paracellular (B) permeability in jejunal explants. Jejunal explants were exposed i) with complete medium (control), ii) with 10^9 CFU/mL *L. rhamnosus* in complete medium, iii) pre-treated with complete medium 1 h and then exposed to $10 \mu\text{M}$ DON in complete medium or iv) pre-incubated 1 h with 10^9 CFU/mL *L. rhamnosus* and then exposed to $10 \mu\text{M}$ DON in complete medium. After 3 h of incubation, transcellular (HRP) and paracellular (FSS) permeability were quantified. Results represent mean and SEM of explants from 6 animals. One-way ANOVA with Bonferroni's multiple comparisons.

Figure 3.





Fig. 3. Effects of *L. rhamnosus* and DON on intestinal inflammation. Jejunal explants were exposed i) with complete medium (control), ii) with 10^9 CFU/mL *L. rhamnosus* in complete medium, iii) pre-treated with complete medium 1 h and then exposed to $10 \mu\text{M}$ DON in complete medium or iv) pre-incubated 1 h with 10^9 CFU/mL *L. rhamnosus* and then exposed to $10 \mu\text{M}$ DON in complete medium. After 3 h of incubation, gene expression was assessed. Relative expression of mRNA encoding for pro-inflammatory cytokines and chemokines was measured by RT-qPCR. Data are normalized to housekeeping gene RPL32 and expressed, in arbitrary unit, as mean and SEM of explants from 6 animals. One-way ANOVA with Bonferroni's multiple comparisons.

Figure 4.

A



B




Fig. 4. Effects of *L. rhamnosus* and DON on activation of MAP Kinases in jejunal explants. Samples were pre-exposed with *L. rhamnosus* 1 h before treatment 30 min with 10 μ M of DON and analyzed by western blot for expression of phosphorylated p42/p44 (A), phosphorylated p38 (B) or non-phosphorylated forms of p42/p44 and p38, used as a protein loading control. Normalized expression graphs were represented. Results as expressed as mean and SEM of explants from 6 animals. One-way ANOVA with Bonferroni's multiple comparisons.

Suppelmentary table 1. Histological lesional score method

Feature scored	Percent of tissue	Score
Number of villi	0	0
	< 15	1
	15 - 25	2
	> 25	3
Enterocytes morphology	flattened enterocytes	0
	> 50% of cubic epithelium	1
	< 49% of cubic epithelium	2
	columnar epithelium	3
Necrotic debris	absent	2
	local	1
	diffuse > 60%	0
Lymphatic vessel dilatation	absent	2
	local	1
	diffuse > 60%	0
Loss of apical enterocytes	absent	2
	local	1
	diffuse > 60%	0
Microvilli morphology	absent	2
	local	1
	diffuse > 60%	0
Villi atrophy	0 - 10 %	3
	11 - 40%	2
	41 - 70%	1
	> 71%	0
Villi fusion	0 - 10 %	3
	11 - 40%	2
	41 - 70%	1
	> 71%	0